EcoDrugPlus

Proteasome 20s Subunit Alpha 8

Ensembl ID : ENSFCAG00000022853
Gene Symbol: PSMA8
5 Cross references
198 Possible Orthologues:

Proteasome 20s Subunit Beta 1

Ensembl ID : ENSFCAG00000031269
Gene Symbol: PSMB1
5 Cross references
217 Possible Orthologues:

Proteasome 20s Subunit Beta 10

Ensembl ID : ENSFCAG00000012854
Gene Symbol: PSMB10
5 Cross references
172 Possible Orthologues:

Proteasome 20s Subunit Beta 2

Ensembl ID : ENSFCAG00000030845
Gene Symbol: PSMB2
5 Cross references
221 Possible Orthologues:

Proteasome 20s Subunit Beta 3

Ensembl ID : ENSFCAG00000014497
Gene Symbol: PSMB3
5 Cross references
225 Possible Orthologues:

Proteasome 20s Subunit Beta 4

Ensembl ID : ENSFCAG00000001861
Gene Symbol: PSMB4
5 Cross references
213 Possible Orthologues:

Proteasome 20s Subunit Beta 5

Ensembl ID : ENSFCAG00000023593
Gene Symbol: PSMB5
5 Cross references
221 Possible Orthologues:

Proteasome 20s Subunit Beta 6

Ensembl ID : ENSFCAG00000036218
Gene Symbol: PSMB6
5 Cross references
211 Possible Orthologues:

Proteasome 20s Subunit Beta 7

Ensembl ID : ENSFCAG00000014567
Gene Symbol: PSMB7
5 Cross references
217 Possible Orthologues:

Proteasome 20s Subunit Beta 8

Ensembl ID : ENSFCAG00000043821
Gene Symbol: PSMB8
4 Cross references
220 Possible Orthologues:

Proteasome 20s Subunit Beta 9

Ensembl ID : ENSFCAG00000044069
Gene Symbol: PSMB9
4 Cross references
213 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 2

Ensembl ID : ENSFCAG00000007793
Gene Symbol: PSMD2
5 Cross references
224 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).